Shinji Akamine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shinji Akamine has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Tadayuki Oka
4 shared publicationsTsutomu Tagawa
4 shared publications- Masashi Muraoka
Department of Surgery, Japan Community Health care Organization (JCHO), Isahaya General Hospital, Japan
3 shared publications Hideki Taniguchi
2 shared publicationsMasao Tomita
2 shared publicationsTakeshi Nagayasu
2 shared publications
Latest Publications
- 1 January 2008
- Published by Elsevier in Clinical Lung Cancer
- Vol. 9 (1) , 44-50
Induction Chemotherapy with Cisplatin, Vinorelbine, and Mitomycin-C Followed by Surgery for Patients with Pathologic N2 Non–Small-Cell Lung Cancer
- 1 January 2008
- Published by Elsevier in Clinical Lung Cancer
- Vol. 9 (1) , 44-50
Induction Chemotherapy with Cisplatin, Vinorelbine, and Mitomycin-C Followed by Surgery for Patients with Pathologic N2 Non–Small-Cell Lung Cancer
- Open Access
- 1 August 2007
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 32 (2) , 356-361
Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer
Objective: It is controversial whether a systematic mediastinal lymph node dissection (MLND) needs to be performed in all patients with stage I lung cancer. The present study was done to examine the new sentinel lymph nodes hypothesis based on the lobe of the primary tumor. Methods: In our first study, the lymph node (LN) metastases were assessed in 291 stage I non-small cell lung cancer (NSCLC) patients who had a major lung resection with a systematic mediastinal lymph node dissection. We evaluated the validity of using our new sentinel lymph nodes method based on the lobe of the primary tumor as follows: the pretracheal (#3), tracheobronchial (#4), and hilar nodes (#10) for right upper lobe tumors; #4, subcarinal (#7), and #10 for middle lobe tumors; the subaortic (#5), paraaortic (#6), and #10 for left upper lobe tumors; and the #7, #10, and interlobar nodes (#11) for tumors in either lower lobes. In the second study, we performed a lobectomy with new sentinel node sampling in 64 patients with preoperative complications. If all of the sampling nodes showed no metastases on frozen section diagnosis, systematic node dissections were not performed. Results: Six of 291 patients in the first study had skip metastases that did not involve the new sentinel nodes; 5 of the 6 patients had macroscopic pleural invasion. Thus, we defined pleural invasion as an exclusion criterion for the second study. In the second study, the median follow-up time was 39 months. Metastatic lymph nodes were detected in 11 of 64 patients. Fifty-three patients (83%) had no metastasis in the sampled nodes, and, therefore, a mediastinal lymph node dissection was not done. The morbidity rate in the sampling group was 36%, and there was no mortality. In the sampling group, local recurrences were observed in two patients, distant metastases in eight, and carcinomatous pleuritis in one; the overall 5-year survival rate was 82%. Conclusions: We found that it is possible to perform a less invasive lymphadenectomy for patients with stage I lung cancer using intra-operative sampling of new sentinel lymph nodes.
- 1 August 2007
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 32 (2) , 356-361
Open AccessSentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer
Objective: It is controversial whether a systematic mediastinal lymph node dissection (MLND) needs to be performed in all patients with stage I lung cancer. The present study was done to examine the new sentinel lymph nodes hypothesis based on the lobe of the primary tumor. Methods: In our first study, the lymph node (LN) metastases were assessed in 291 stage I non-small cell lung cancer (NSCLC) patients who had a major lung resection with a systematic mediastinal lymph node dissection. We evaluated the validity of using our new sentinel lymph nodes method based on the lobe of the primary tumor as follows: the pretracheal (#3), tracheobronchial (#4), and hilar nodes (#10) for right upper lobe tumors; #4, subcarinal (#7), and #10 for middle lobe tumors; the subaortic (#5), paraaortic (#6), and #10 for left upper lobe tumors; and the #7, #10, and interlobar nodes (#11) for tumors in either lower lobes. In the second study, we performed a lobectomy with new sentinel node sampling in 64 patients with preoperative complications. If all of the sampling nodes showed no metastases on frozen section diagnosis, systematic node dissections were not performed. Results: Six of 291 patients in the first study had skip metastases that did not involve the new sentinel nodes; 5 of the 6 patients had macroscopic pleural invasion. Thus, we defined pleural invasion as an exclusion criterion for the second study. In the second study, the median follow-up time was 39 months. Metastatic lymph nodes were detected in 11 of 64 patients. Fifty-three patients (83%) had no metastasis in the sampled nodes, and, therefore, a mediastinal lymph node dissection was not done. The morbidity rate in the sampling group was 36%, and there was no mortality. In the sampling group, local recurrences were observed in two patients, distant metastases in eight, and carcinomatous pleuritis in one; the overall 5-year survival rate was 82%. Conclusions: We found that it is possible to perform a less invasive lymphadenectomy for patients with stage I lung cancer using intra-operative sampling of new sentinel lymph nodes.
- Open Access
- 1 January 2005
- Published by Japan Lung Cancer Society in Haigan
- Vol. 45 (4) , 335-341
Surgical Treatment for Multiple Primary Lung Cancer
目的. 多発肺癌に対する外科治療成績を検討し, 手術適応と術式選択につき検討する. 対象と方法. 臨床病理学的に多発肺癌と診断した64例を対象とした. 結果. 平均年齢64.3歳, 男女比49:15, 同時性27, 異時性37例. 組織型は共に腺癌27, 共に扁平上皮癌14, 腺癌―扁平上皮癌11例で, 病期は共にI期35, I・II期14例. 同時性では一期的手術14例, 二期的手術11例で, 複数回手術43例の初回手術は肺葉切除 (27例) が多く, 2回目は縮小手術が多かった (28例). 4例に両側肺葉切除, 3例に残存肺全摘術を行った. 術死および重篤な術後合併症は認めなかった. 予後は異時性が術後5年生存率 (5生率) 74.9%, 同時性は63.9%であった. 異時性で二次癌がIA期では5生率85.1%, IB期で66.7%, II期以上は有意に予後不良であった. 組織型では共に腺癌 (81.5%) が最も良好であった. 結論. 多発肺癌に対する外科治療は合併症も少なく安全に施行できた. 二次癌に対しても, 残存肺機能やperformance statusがよい症例には, 両側肺葉切除や残存肺全摘術も可能である. 特にI期症例では予後も期待でき, 積極的に外科治療を行うべきである.
- 1 January 2005
- Published by Japan Lung Cancer Society in Haigan
- Vol. 45 (4) , 335-341
Open AccessSurgical Treatment for Multiple Primary Lung Cancer
目的. 多発肺癌に対する外科治療成績を検討し, 手術適応と術式選択につき検討する. 対象と方法. 臨床病理学的に多発肺癌と診断した64例を対象とした. 結果. 平均年齢64.3歳, 男女比49:15, 同時性27, 異時性37例. 組織型は共に腺癌27, 共に扁平上皮癌14, 腺癌―扁平上皮癌11例で, 病期は共にI期35, I・II期14例. 同時性では一期的手術14例, 二期的手術11例で, 複数回手術43例の初回手術は肺葉切除 (27例) が多く, 2回目は縮小手術が多かった (28例). 4例に両側肺葉切除, 3例に残存肺全摘術を行った. 術死および重篤な術後合併症は認めなかった. 予後は異時性が術後5年生存率 (5生率) 74.9%, 同時性は63.9%であった. 異時性で二次癌がIA期では5生率85.1%, IB期で66.7%, II期以上は有意に予後不良であった. 組織型では共に腺癌 (81.5%) が最も良好であった. 結論. 多発肺癌に対する外科治療は合併症も少なく安全に施行できた. 二次癌に対しても, 残存肺機能やperformance statusがよい症例には, 両側肺葉切除や残存肺全摘術も可能である. 特にI期症例では予後も期待でき, 積極的に外科治療を行うべきである.
- Open Access
- 1 March 2003
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 2 (1) , 58-60
Thoracoscopic drainage with wound edge protector for descending necrotizing mediastinitis
It has recently been found that wide recognition of descending necrotizing mediastinitis (DNM) and its resultant early diagnosis can reduce the high mortality rate associated with this disease by allowing for rapid surgical intervention. Nevertheless, thoracotomy remains controversial as a treatment for DNM. We report a successful case of DNM in which the mediastinitis had spread below the carina and which was treated by drainage through cervicotomy and by thoracoscopic drainage with mini-thoracotomy using the newly available wound edge protector called a Lap-protector.
- 1 March 2003
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 2 (1) , 58-60
Open AccessThoracoscopic drainage with wound edge protector for descending necrotizing mediastinitis
It has recently been found that wide recognition of descending necrotizing mediastinitis (DNM) and its resultant early diagnosis can reduce the high mortality rate associated with this disease by allowing for rapid surgical intervention. Nevertheless, thoracotomy remains controversial as a treatment for DNM. We report a successful case of DNM in which the mediastinitis had spread below the carina and which was treated by drainage through cervicotomy and by thoracoscopic drainage with mini-thoracotomy using the newly available wound edge protector called a Lap-protector.
- 1 June 1993
- Published by Wolters Kluwer Health in Transplantation
- Vol. 55 (6) , 1438-1439
THE EFFECT OF THE PLATELET-ACTIVATING FACTOR INHIBITOR TCV-309 ON REPERFUSION INJURY IN A CANINE MODEL OF ISCHEMIC LUNG
- 1 June 1993
- Published by Wolters Kluwer Health in Transplantation
- Vol. 55 (6) , 1438-1439
THE EFFECT OF THE PLATELET-ACTIVATING FACTOR INHIBITOR TCV-309 ON REPERFUSION INJURY IN A CANINE MODEL OF ISCHEMIC LUNG
- 1 January 1988
- Published by Japan Surgical Association in The journal of the Japanese Practical Surgeon Society
- Vol. 49 (7) , 1200-1202
FOUR CASES OF CHYLOTHORAX FOLLOWING THORACOTOMY
- 1 January 1988
- Published by Japan Surgical Association in The journal of the Japanese Practical Surgeon Society
- Vol. 49 (7) , 1200-1202
FOUR CASES OF CHYLOTHORAX FOLLOWING THORACOTOMY